Gilead Sciences hires NSC for hepatitis B deal

US-based Gilead Sciences has drafted in its first UK PR support in the hepatitis B disease area.

Gilead, the California-headquartered firm behind anti-hepatitis B product Hepsera, has appointed Nexus Structured Communications for a two-year campaign to ‘raise awareness’ of hepatitis B among UK opinion formers.

NSC managing director Geoffrey Bowden, who reports to Hepsera UK and Ireland product manager Nigel Hughes, said: ‘Hepatitis B carries with it all the stigma associated with Aids in the early 1980s. It is essential to give hepatitis B a platform.’

Submissions to NICE for its upcoming appraisal of chronic hepatitis B treatments are due next February.

Gilead continues to retain Weber Shandwick on a global hepatitis B remit. Meanwhile, NSC has appointed former CancerBACUP head of comms Mark Winkless as associate director.

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in